‘Reimbursing Padcev is urgent to treat severe urothelial cancer with no alternative …
However, the advent of antibody-drug conjugates (ADCs) has changed the treatment of urothelial cancer. In addition to providing a new option as a last …
However, the advent of antibody-drug conjugates (ADCs) has changed the treatment of urothelial cancer. In addition to providing a new option as a last …